


TO:Auto-reply fax to 858 720 2555 COMPANY:

## Auto-Reply Facsimile Transmission



TO: Fax Sender at 858 720 2555

Fax Information

Date Received:

Total Pages:

10/1/03 7:15:35 PM [Eastern Daylight Time]

24 (including cover page)

**ADVISORY:** This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received  
Cover  
Page  
=====

01/10 2003 10:08 FAX 858 720 2555 PAUL HASTINGS 001  
 Paul, Hastings, Janofsky & Walker LLP  
 3579 Valley Centre Drive, San Diego, CA 92130  
 telephone 858-720-2500 / facsimile 858-720-2555 / [www.paulhastings.com](http://www.paulhastings.com)

Paul Hastings

**FACSIMILE TRANSMISSION**

from:	facsimile:	telephone:	initials:
-------	------------	------------	-----------

Diana L. Bush, Ph.D., Esq.	(858) 720-2555	(858) 720-2885	DLB4
----------------------------	----------------	----------------	------

client name:	Metabasis Therapeutics, Inc.	client matter number:	45198.00027.CON1
--------------	------------------------------	-----------------------	------------------

date:	October 1, 2003	pages (with cover):	24
-------	-----------------	---------------------	----

to:	company/office:	facsimile:	telephone:
-----	-----------------	------------	------------

Examiner Cameron Jones	USPTO	703 872-9306	703 308-4640
------------------------	-------	--------------	--------------

comments:

U. S. Patent Application No. 09/978,454  
**NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS**  
 Applicant: Exion, et al.  
 Filing Date: October 15, 2001  
 Our Ref: 45198.00027.CON1

Attached hereto are the following documents for filing in the above patent application:

1. Fee Transmittal Sheet
2. Petition for Extension of Time & Response to Office Action
3. Terminal Disclaimer under 37 C.F.R. §1.321(b)

**CERTIFICATE OF TRANSMISSION**  
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

October 1, 2003

Name of Person Transmitting Paper

Signature of Person Transmitting Paper

If you do not receive all pages, please call Immediately Facsimile Center: (858) 720-2903

This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, please do not use, copy, disseminate, distribute or forward this communication. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

\*\*\*\*\*  
 \*\*\* TX REPORT \*\*\*  
 \*\*\*\*\*

TRANSMISSION OK

TX/RX NO	1252
CONNECTION TEL	##145168##17038729306#
CONNECTION ID	
ST. TIME	01/10 16:08
USAGE T	06 '18
PGS. SENT	24
RESULT	OK

Paul, Hastings, Janofsky & Walker LLP  
 3579 Valley Centre Drive, San Diego, CA 92130  
 telephone 858-720-2500 / facsimile 858-720-2555 / www.paulhastings.com

Paul Hastings

**FACSIMILE TRANSMISSION**

<b>from:</b>	<b>facsimile:</b>	<b>telephone:</b>	<b>Initials:</b>
Diana L. Bush, Ph.D., Esq.	(858) 720-2555	(858) 720-2885	DLB4

<b>client name:</b> Metabasis Therapeutics, Inc.	<b>client matter number:</b>	45198.00027.CON1
<b>date:</b> October 1, 2003	<b>pages (with cover):</b>	24

<b>to:</b>	<b>company/office:</b>	<b>facsimile:</b>	<b>telephone:</b>
Examiner Dameron Jones Art Unit 1616	USPTO	703 872-9306	703 308-4640

**comments:**

U. S. Patent Application No. 09/978,454

**NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS**

Applicant: Erion, et al.

Filing Date: October 15, 2001

Our Ref: 45198.00027.CON1

Attached hereto are the following documents for filing in the above patent application:

1. Fee Transmittal Sheet
2. Petition for Extension of Time & Response to Office Action
3. Terminal Disclaimer under 37 C.F.R. §1.321(B)

---

**CERTIFICATE OF TRANSMISSION**  
 (37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

Jill C. Yankel

1)

Paul, Hastings, Janofsky & LLP  
3579 Valley Centre Drive, San Diego, CA 92130  
telephone 858-720-2500 / facsimile 858-720-2555 / www.paulhastings.com

Paul Hastings

**FACSIMILE TRANSMISSION**

**from:** Diana L. Bush, Ph.D., Esq. **facsimile:** (858) 720-2555 **telephone:** (858) 720-2885 **initials:** DLB4

**client name:** Metabasis Therapeutics, Inc. **client matter number:** 45198.00027.CON1

**date:** October 1, 2003 **pages (with cover):** 24

**to:** Examiner Dameron Jones **company/office:** USPTO **facsimile:** 703 872-9306 **telephone:** 703 308-4640

**Art Unit 1616**

**comments:**

U. S. Patent Application No. 09/978,454

**NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS**

Applicant: Erion, et al.

Filing Date: October 15, 2001

Our Ref: 45198.00027.CON1

Attached hereto are the following documents for filing in the above patent application:

1. Fee Transmittal Sheet
2. Petition for Extension of Time & Response to Office Action
3. Terminal Disclaimer under 37 C.F.R. §1.321(B)

---

**CERTIFICATE OF TRANSMISSION**  
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

Jill C. Youkel  
Name of Person Transmitting Paper

October 1, 2003  
Date of Transmission

Jill C. Youkel  
Signature of Person Transmitting Paper

**If you do not receive all pages, please call immediately Facsimile Center: (858) 720-2903**

*This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 1,040.00)

## Complete if Known

Application Number	09/978,454
Filing Date	October 15, 2001
First Named Inventor	Erion, et al.
Examiner Name	Dameron Jones
Art Unit	1616
Attorney Docket No.	45198.00027.CON1

## METHOD OF PAYMENT (check all that apply)

 Check  Credit card  Money Order  Other  None
 Deposit Account:

Deposit Account Number  
50-2613

Deposit Account Name

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below  Credit any overpayments

Charge any additional fee(s) during the pendency of this application

Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION (continued)


## 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
1051	130	2051 65 Surcharge - late filing fee or oath	
1052	50	2052 25 Surcharge - late provisional filing fee or cover sheet	
1053	130	1053 130 Non-English specification	
1812	2,520	1812 2,520 For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804 920* Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805 1,840* Requesting publication of SIR after Examiner action	
1251	110	2251 55 Extension for reply within first month	
1252	410	2252 205 Extension for reply within second month	
1253	930	2253 465 Extension for reply within third month	
1254	1,450	2254 725 Extension for reply within fourth month	
1255	1,970	2255 985 Extension for reply within fifth month	
1401	320	2401 160 Notice of Appeal	
1402	320	2402 160 Filing a brief in support of an appeal	
1403	280	2403 140 Request for oral hearing	
1451	1,510	1451 1,510 Petition to institute a public use proceeding	
1452	110	2452 55 Petition to revive - unavoidable	
1453	1,300	2453 650 Petition to revive - unintentional	
1501	1,300	2501 650 Utility issue fee (or reissue)	
1502	470	2502 235 Design issue fee	
1503	630	2503 315 Plant issue fee	
1460	130	1460 130 Petitions to the Commissioner	
1807	50	1807 50 Processing fee under 37 CFR 1.17(q)	
1806	180	1806 180 Submission of Information Disclosure Stmt	
8021	40	8021 40 Recording each patent assignment per property (times number of properties)	
1809	750	2809 375 Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810 375 For each additional invention to be examined (37 CFR 1.129(b))	
1801	750	2801 375 Request for Continued Examination (RCE)	
1802	900	1802 900 Request for expedited examination of a design application	
Other fee(s) <input type="checkbox"/> Terminal Disclaimer			110.00
*Reduced by Basic Filing Fee Paid			
SUBTOTAL (3) (\$ 1,040.00)			

\*\*or number previously paid, if greater; For Reissues, see above

## SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Diana L. Bush, Ph.D., Esq.	Registration No. (Attorney/Agent)	51,109	Telephone	858 720-2500
Signature				Date	October 1, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Erion *et al.*

Serial No.: 09/978,454

Filed: October 15, 2001

Title: NOVEL PRODRUGS FOR  
PHOSPHORUS-CONTAINING  
COMPOUNDS

Group Art Unit: 1616

Examiner: Dameron Jones

**AMENDMENT AND REMARKS  
&  
PETITION FOR EXTENSION OF TIME**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby petition for a 3-month extension of time under 37 CFR § 1.136(a).

With the granting of said extension, it is believed that this response is timely filed. The Commissioner is hereby authorized to charge Deposit Account No. 50-2613 for the 3-month extension fee due herein and any other fees that may become due or credit become payable during the pendency of this application. The amendment and response address the issues raised by the Examiner in an Office Action, dated April 1, 2003.


**CERTIFICATE OF TRANSMISSION  
(37 C.F.R. §1.8)**

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

JILL C. YOUKEL  
Name of Person Transmitting Paper

October 1, 2003  
Date of Transmission

Signature of Person Transmitting Paper




**AMENDMENT**

In the claims:

Please amend the claims as indicated below. A complete set of all claims previously submitted, including the status for each claim, immediately follows below.

1.-167. (Cancelled)

168. (Previously added) A pharmaceutical composition comprising a compound of Formula I:



Formula I

wherein:

V, W and W' are independently selected from the group consisting of hydrogen, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein the cyclic group optionally contains one heteroatom and is substituted with a hydroxy, acyloxy, alkoxy carbonyloxy, or aryloxy carbonyloxy group attached to a carbon atom that is three atoms away from both oxygen atoms that are attached to the phosphorus atom; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group wherein the cyclic group optionally contains one heteroatom, and is fused to an aryl group, at the beta and gamma position to the oxygen attached to the phosphorus; or

together V and W are connected via an additional three carbon atoms to form an optionally substituted cyclic group containing six carbon atoms and is optionally substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy groups, wherein such substituent is attached to one of said carbon atoms that is three atoms away from an oxygen attached to the phosphorus atom; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

Z is selected from  $-\text{CHR}^2\text{OH}$ ,  $-\text{CHR}^2\text{OC(O)R}^3$ ,  $-\text{CHR}^2\text{OC(S)R}^3$ ,  $-\text{CHR}^2\text{OC(S)OR}^3$ ,  $-\text{CHR}^2\text{OC(O)SR}^3$ ,  $-\text{CHR}^2\text{OCO}_2\text{R}^3$ ,  $-\text{OR}^2$ ,  $-\text{SR}^2$ ,  $-\text{CHR}^2\text{N}_3$ ,  $-\text{CH}_2(\text{aryl})$ ,  $-\text{CH}(\text{aryl})\text{OH}$ ,  $-\text{CH}(\text{CH}=\text{CR}^2_2)\text{OH}$ ,  $-\text{CH}(\text{C}\equiv\text{CR}^2)\text{OH}$ ,  $-\text{R}^2$ ,  $-\text{NR}^2_2$ ,  $-\text{OC(O)R}^3$ ,  $-\text{OCO}_2\text{R}^3$ ,  $-\text{SC(O)R}^3$ ,  $-\text{SCO}_2\text{R}^3$ ,  $-\text{NHC(O)R}^2$ ,  $-\text{NHCO}_2\text{R}^3$ ,  $-\text{CH}_2\text{NH}(\text{aryl})$ ,  $-(\text{CH}_2)_p\text{OR}^{12}$ , and  $-(\text{CH}_2)_p\text{SR}^{12}$ ;

$\text{R}^2$  is selected from the group consisting of  $\text{R}^3$  and hydrogen;

$\text{R}^3$  is selected from the group consisting of alkyl, aryl, alicyclic, and aralkyl;

$\text{R}^{12}$  is selected from the group consisting of hydrogen, and lower acyl; and

$\text{p}$  is an integer 2 or 3;

with the provisos that:

- a) V, Z, W, and W' are not all hydrogen; and
- b) when Z is  $-\text{R}^2$ , then at least one of V, W, and W' is not hydrogen, alkyl, aralkyl, or alicyclic; and

M is selected from the group that, attached to  $\text{PO}_3^{2-}$ ,  $\text{P}_2\text{O}_6^{3-}$ , or  $\text{P}_3\text{O}_9^{4-}$ , is biologically active *in vivo* and that is attached to the phosphorus atom in Formula I via a carbon, oxygen, or nitrogen atom, with the proviso that  $\text{M-PO}_3^{2-}$  is not an FBPase inhibitor;

wherein said compound of Formula I is converted to  $\text{MPO}_3\text{H}_2$  by human liver microsomes;

pharmaceutically acceptable salts of Formula I;

and a pharmaceutically acceptable excipient.

169. (Previously Amended) The pharmaceutical composition of claim 168, wherein MH is 9-(2-phosphonylmethoxyethyl)adenine (PMEA) or analogues thereof.

170. (Previously Amended) The pharmaceutical composition of claim 168, wherein MH is 9-(2-phosphonylmethoxyethyl)adenine (PMEA).

171. (Previously Amended) The pharmaceutical composition of claim 168, wherein MH is selected from penciclovir, 3TC, ACV, PMPA, araC, ribavirin, fludarabine, and 5-fluoro-2'-deoxyuridine.

172. (Previously Amended) The pharmaceutical composition of claim 168, wherein MH is radiolabelled 2'-deoxy-5-Iodouridine.

173. (Previously Amended) The pharmaceutical composition of claim 172 wherein MH is 2'-deoxy-5- $^{131}\text{I}$ -iodouridine.

174. (Previously Amended) The pharmaceutical composition of claim 168, wherein V is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

175. (Previously Amended) The pharmaceutical composition of claim 168, wherein the prodrug is in the *cis* configuration.


176. (Previously Amended) The pharmaceutical composition of claim 174, wherein the prodrug is in the *cis* configuration.

177. (Previously Amended) The pharmaceutical composition of Claim 171, wherein MH is araC and V is a heteroaryl group.

178. (Previously Amended) The pharmaceutical composition of claim 177, wherein V is 4-pyridyl.

179. (Previously Amended) The pharmaceutical composition of claim 172 wherein MH is 2'-deoxy-5-<sup>125</sup>I-iodouridine.

180. (Previously added) A pharmaceutical composition comprising a compound of Formula I:



Formula I

wherein:

V, W and W' are independently selected from the group consisting of hydrogen, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and

1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein the cyclic group optionally contains one heteroatom and is substituted with a hydroxy, acyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy group attached to a carbon atom that is three atoms away from both oxygen atoms that are attached to the phosphorus atom; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group wherein the cyclic group optionally contains one heteroatom, and is fused to an aryl group, at the beta and gamma position to the oxygen attached to the phosphorus; or

together V and W are connected via an additional three carbon atoms to form an optionally substituted cyclic group containing six carbon atoms and is optionally substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy groups, wherein such substituent is attached to one of said carbon atoms that is three atoms away from an oxygen attached to the phosphorus atom; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

Z is selected from  $-\text{CHR}^2\text{OH}$ ,  $-\text{CHR}^2\text{OC(O)R}^3$ ,  $-\text{CHR}^2\text{OC(S)R}^3$ ,  $-\text{CHR}^2\text{OC(S)OR}^3$ ,  $-\text{CHR}^2\text{OC(O)SR}^3$ ,  $-\text{CHR}^2\text{OCO}_2\text{R}^3$ ,  $-\text{OR}^2$ ,  $-\text{SR}^2$ ,  $-\text{CHR}^2\text{N}_3$ ,  $-\text{CH}_2(\text{aryl})$ ,  $-\text{CH}(\text{aryl})\text{OH}$ ,  $-\text{CH}(\text{CH}=\text{CR}^2_2)\text{OH}$ ,  $-\text{CH}(\text{C}\equiv\text{CR}^2)\text{OH}$ ,  $-\text{R}^2$ ,  $-\text{NR}^2_2$ ,  $-\text{OC(O)R}^3$ ,  $-\text{OCO}_2\text{R}^3$ ,  $-\text{SC(O)R}^3$ ,  $-\text{SCO}_2\text{R}^3$ ,  $-\text{NHC(O)R}^2$ ,  $-\text{NHCO}_2\text{R}^3$ ,  $-\text{CH}_2\text{NH}(\text{aryl})$ ,  $-(\text{CH}_2)_p\text{OR}^{12}$ , and  $-(\text{CH}_2)_p\text{SR}^{12}$ ;

$\text{R}^2$  is selected from the group consisting of  $\text{R}^3$  and hydrogen;

$\text{R}^3$  is selected from the group consisting of alkyl, aryl, alicyclic, and aralkyl;

$\text{R}^{12}$  is selected from the group consisting of hydrogen, and lower acyl; and

$\text{p}$  is an integer 2 or 3;

with the provisos that:


- a) V, Z, W, and W' are not all hydrogen; and
- b) when Z is  $-R^2$ , then at least one of V, W, and W' is not hydrogen, alkyl, aralkyl, or alicyclic; and

M is selected from the group that, attached to  $PO_3^{2-}$ ,  $P_2O_6^{3-}$ , or  $P_3O_9^{4-}$ , is biologically active *in vivo* and that is attached to the phosphorus atom in Formula I via a carbon atom, with the proviso that  $MPO_3^{2-}$  is not an FBPase inhibitor;

wherein said compound of Formula I is converted to  $MPO_3H_2$  by human liver microsomes;

pharmaceutically acceptable prodrugs and salts of Formula I;  
and a pharmaceutically acceptable excipient.

181. (Previously added) A pharmaceutical composition comprising a compound of Formula I:



Formula I

wherein:

V, W and W' are independently selected from the group consisting of hydrogen, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein the cyclic group optionally contains one heteroatom and is substituted with a hydroxy, acyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy group attached

to a carbon atom that is three atoms away from both oxygen atoms that are attached to the phosphorus atom; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group wherein the cyclic group optionally contains one heteroatom, and is fused to an aryl group, at the beta and gamma position to the oxygen attached to the phosphorus; or

together V and W are connected via an additional three carbon atoms to form an optionally substituted cyclic group containing six carbon atoms and is optionally substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy groups, wherein such substituent is attached to one of said carbon atoms that is three atoms away from an oxygen attached to the phosphorus atom; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

Z is selected from  $-\text{CHR}^2\text{OH}$ ,  $-\text{CHR}^2\text{OC(O)R}^3$ ,  $-\text{CHR}^2\text{OC(S)R}^3$ ,  $-\text{CHR}^2\text{OC(S)OR}^3$ ,  $-\text{CHR}^2\text{OC(O)SR}^3$ ,  $-\text{CHR}^2\text{OCO}_2\text{R}^3$ ,  $-\text{OR}^2$ ,  $-\text{SR}^2$ ,  $-\text{CHR}^2\text{N}_3$ ,  $-\text{CH}_2(\text{aryl})$ ,  $-\text{CH}(\text{aryl})\text{OH}$ ,  $-\text{CH}(\text{CH}=\text{CR}^2_2)\text{OH}$ ,  $-\text{CH}(\text{C}\equiv\text{CR}^2)\text{OH}$ ,  $-\text{R}^2$ ,  $-\text{NR}^2_2$ ,  $-\text{OC(O)R}^3$ ,  $-\text{OCO}_2\text{R}^3$ ,  $-\text{SC(O)R}^3$ ,  $-\text{SCO}_2\text{R}^3$ ,  $-\text{NHC(O)R}^2$ ,  $-\text{NHCO}_2\text{R}^3$ ,  $-\text{CH}_2\text{NH}(\text{aryl})$ ,  $-(\text{CH}_2)_p\text{OR}^{12}$ , and  $-(\text{CH}_2)_p\text{SR}^{12}$ ;

$\text{R}^2$  is selected from the group consisting of  $\text{R}^3$  and hydrogen;

$\text{R}^3$  is selected from the group consisting of alkyl, aryl, alicyclic, and aralkyl;

$\text{R}^{12}$  is selected from the group consisting of hydrogen, and lower acyl; and

$\text{p}$  is an integer 2 or 3;

with the provisos that:


- a) V, Z, W, and W' are not all hydrogen; and
- b) when Z is  $-\text{R}^2$ , then at least one of V, W, and W' is not hydrogen, alkyl, aralkyl, or alicyclic; and

M is selected from the group that, attached to  $\text{PO}_3^{2-}$ ,  $\text{P}_2\text{O}_6^{3-}$ , or  $\text{P}_3\text{O}_9^{4-}$ , is biologically active *in vivo* and that is attached to the phosphorus atom in Formula I via an oxygen atom, with the proviso that  $\text{MPO}_3^{2-}$  is not an FBPase inhibitor;

wherein said compound of Formula I is converted to  $\text{MPO}_3\text{H}_2$  by human liver microsomes;

pharmaceutically acceptable prodrugs and salts of Formula I;  
and a pharmaceutically acceptable excipient.

182. (Previously added) A pharmaceutical composition comprising a compound of Formula I:



Formula I

wherein:

V, W and W' are independently selected from the group consisting of hydrogen, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein the cyclic group optionally contains one heteroatom and is substituted with a hydroxy, acyloxy, alkoxy carbonyloxy, or aryloxy carbonyloxy group attached to a carbon atom that is three atoms away from both oxygen atoms that are attached to the phosphorus atom; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group wherein the cyclic group optionally contains one heteroatom, and is fused to an aryl group, at the beta and gamma position to the oxygen attached to the phosphorus; or

together V and W are connected via an additional three carbon atoms to form an optionally substituted cyclic group containing six carbon atoms and is optionally substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxy carbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy groups, wherein such substituent is attached to one of said carbon atoms that is three atoms away from an oxygen attached to the phosphorus atom; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

Z is selected from  $-\text{CHR}^2\text{OH}$ ,  $-\text{CHR}^2\text{OC(O)R}^3$ ,  $-\text{CHR}^2\text{OC(S)R}^3$ ,  $-\text{CHR}^2\text{OC(S)OR}^3$ ,  $-\text{CHR}^2\text{OC(O)SR}^3$ ,  $-\text{CHR}^2\text{OCO}_2\text{R}^3$ ,  $-\text{OR}^2$ ,  $-\text{SR}^2$ ,  $-\text{CHR}^2\text{N}_3$ ,  $-\text{CH}_2(\text{aryl})$ ,  $-\text{CH}(\text{aryl})\text{OH}$ ,  $-\text{CH}(\text{CH}=\text{CR}^2)\text{OH}$ ,  $-\text{CH}(\text{C}\equiv\text{CR}^2)\text{OH}$ ,  $-\text{R}^2$ ,  $-\text{NR}^2$ ,  $-\text{OC(O)R}^3$ ,  $-\text{OCO}_2\text{R}^3$ ,  $-\text{SC(O)R}^3$ ,  $-\text{SCO}_2\text{R}^3$ ,  $-\text{NHC(O)R}^2$ ,  $-\text{NHCO}_2\text{R}^3$ ,  $-\text{CH}_2\text{NH}(\text{aryl})$ ,  $-(\text{CH}_2)_p\text{OR}^{12}$ , and  $-(\text{CH}_2)_p\text{SR}^{12}$ ;

$\text{R}^2$  is selected from the group consisting of  $\text{R}^3$  and hydrogen;

$\text{R}^3$  is selected from the group consisting of alkyl, aryl, alicyclic, and aralkyl;

$\text{R}^{12}$  is selected from the group consisting of hydrogen, and lower acyl; and

$\text{p}$  is an integer 2 or 3;

with the provisos that:


- a) V, Z, W, and W' are not all hydrogen; and
- b) when Z is  $-\text{R}^2$ , then at least one of V, W, and W' is not hydrogen, alkyl, aralkyl, or alicyclic; and

M is selected from the group that, attached to  $\text{PO}_3^{2-}$ ,  $\text{P}_2\text{O}_6^{3-}$ , or  $\text{P}_3\text{O}_9^{4-}$ , is biologically active *in vivo* and that is attached to the phosphorus atom in Formula I via a nitrogen atom, with the proviso that  $\text{MPO}_3^{2-}$  is not an FBPase inhibitor;

wherein said compound of Formula I is converted to  $\text{MPO}_3\text{H}_2$  by human liver microsomes;

pharmaceutically acceptable prodrugs and salts of Formula I;  
and a pharmaceutically acceptable excipient.

183. (Currently amended) A pharmaceutical composition comprising a compound of Formula I:



Formula I

wherein:

W and W' are independently selected from the group of H, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and 1-alkynyl;

V is selected from the group of aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkynyl and 1-alkenyl;

Z is selected from  $-\text{CHR}^2\text{OH}$ ,  $-\text{CHR}^2\text{OC(O)R}^3$ ,  $-\text{CHR}^2\text{OC(S)R}^3$ ,  $-\text{CHR}^2\text{OC(S)OR}^3$ ,  $-\text{CHR}^2\text{OC(O)SR}^3$ ,  $-\text{CHR}^2\text{OCO}_2\text{R}^3$ ,  $-\text{OR}^2$ ,  $-\text{SR}^2$ ,  $-\text{CHR}^2\text{N}_3$ ,  $-\text{CH}_2(\text{aryl})$ ,  $-\text{CH}(\text{aryl})\text{OH}$ ,  $-\text{CH}(\text{CH}=\text{CR}^2_2)\text{OH}$ ,  $-\text{CH}(\text{C}\equiv\text{CR}^2)\text{OH}$ ,  $-\text{R}^2$ ,  $-\text{NR}^2$ ,  $-\text{OC(O)R}^3$ ,  $-\text{OCO}_2\text{R}^3$ ,  $-\text{SC(O)R}^3$ ,  $-\text{SCO}_2\text{R}^3$ ,  $-\text{NHC(O)R}^2$ ,  $-\text{NHCO}_2\text{R}^3$ ,  $-\text{CH}_2\text{NH}(\text{aryl})$ ,  $-(\text{CH}_2)_p\text{OR}^{12}$ , and  $-(\text{CH}_2)_p\text{SR}^{12}$ ; or

together V and Z are connected via 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the oxygen attached to the phosphorus;

p is an integer 2 or 3;

R<sup>2</sup> is selected from the group of R<sup>3</sup> and -H;

R<sup>3</sup> is selected from the group of alkyl, aryl, alicyclic, and aralkyl;

R<sup>12</sup> is selected from the group consisting of hydrogen, and lower acyl; and


M is selected from the group that, attached to PO<sub>3</sub><sup>2-</sup>, P<sub>2</sub>O<sub>6</sub><sup>3-</sup>, or P<sub>3</sub>O<sub>9</sub><sup>4-</sup>, is biologically active *in vivo* and that is attached to the phosphorus atom in Formula I via a carbon, oxygen, or nitrogen atom;

wherein said compound of formula I is converted to MPO<sub>3</sub>H<sub>2</sub> by human liver microsomes, with the proviso that M-PO<sub>3</sub><sup>2-</sup> is not an FBPase inhibitor;

pharmaceutically acceptable prodrugs and salts of Formula I;

and a pharmaceutically acceptable excipient.

184. (Currently amended) A pharmaceutical composition comprising a compound of Formula I:



Formula I

wherein:

V, W and W' are independently selected from the group of -H, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and 1-alkynyl;

Z is selected from the group of:  $-\text{CHR}^2\text{OH}$ ,  $-\text{CHR}^2\text{OC(O)R}^3$ ,  $-\text{CHR}^2\text{OC(S)R}^3$ ,  $-\text{CHR}^2\text{OCO}_2\text{R}^3$ ,  $-\text{CHR}^2\text{OC(O)SR}^3$ ,  $-\text{CHR}^2\text{OC(S)OR}^3$ ,  $-\text{CH(aryl)OH}$ ,  $-\text{CH}(\text{CH}=\text{CR}^2)\text{OH}$ ,  $-\text{CH}(\text{C}\equiv\text{CR}^2)\text{OH}$ ,  $-\text{SR}^2$ ,  $-\text{CH}_2\text{NHaryl}$ ,  $-\text{CH}_2\text{ aryl}$ ; or

together V and Z are connected via 3-5 carbon atoms to form a cyclic group, optionally containing heteroatom, substituted with hydroxy, acyloxy, alkoxy carbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from an oxygen attached to phosphorus;

$\text{R}^2$  is selected from the group of  $\text{R}^3$  and H;


$\text{R}^3$  is selected from the group of alkyl, aryl, alicyclic, and aralkyl; and

M is selected from the group that, attached to  $\text{PO}_3^{2-}$ ,  $\text{P}_2\text{O}_6^{3-}$ , or  $\text{P}_3\text{O}_9^{4-}$ , is biologically active *in vivo* and that is attached to the phosphorus atom in Formula I via a carbon, oxygen, or nitrogen atom;

wherein said compound of formula I is converted to  $\text{MPO}_3\text{H}_2$  by human liver microsomes, with the proviso that  $\text{M-PO}_3^{2-}$  is not an FBPase inhibitor

pharmaceutically acceptable prodrugs and salts of Formula I;  
and a pharmaceutically acceptable excipient.

185. (Currently amended) A pharmaceutical composition comprising a compound of Formula VIII:



wherein:

$\text{Z}'$  is selected from the group of  $-\text{OH}$ ,  $-\text{OC(O)R}^3$ ,  $-\text{OCO}_2\text{R}^3$ , and  $-\text{OC(O)SR}^3$ ;

$\text{D}^4$  and  $\text{D}^3$  are independently selected from the group of  $-\text{H}$ , alkyl,  $-\text{OR}^2$ ,  $-\text{OH}$ , and  $-\text{OC(O)R}^3$ ; with the proviso that at least one of  $\text{D}^4$  and  $\text{D}^3$  are  $-\text{H}$ ;

$R^2$  is selected from the group of  $R^3$  and H;

$R^3$  is selected from the group of alkyl, aryl, alicyclic, and aralkyl; and

M is selected from the group that, attached to  $PO_3^{2-}$ ,  $P_2O_6^{3-}$ , or  $P_3O_9^{4-}$ , is biologically active *in vivo* and that is attached to the phosphorus atom in Formula I via a carbon, oxygen, or nitrogen atom;

wherein said compound of formula I is converted to  $MPO_3H_2$  by human liver microsomes, with the proviso that  $M-PO_3^{2-}$  is not an FBPase inhibitor;

and pharmaceutically acceptable prodrugs and salts of Formula VIII;

and a pharmaceutically acceptable excipient.--

## REMARKS

Claims 168-185 are pending. Claims 183-185 have been amended. No new matter was added to the claims. Support for the amendments can be found throughout the specification, for example at p. 21, lines 8-10.

All pending claims stand rejected. The Examiner also notes that claims 168-185 are distinguished over the prior art of record.

All of the above changes are cosmetic and none raise any issue of patentability. Both before and after the above changes, the invention was described in full, clear, concise, and exact terms and met all conditions for patentability under 35 USC 101 *et seq*. The scope of the claims of any resulting patent (and any and all limitations in any of said claims) shall not under any circumstances be limited to their literal terms, but are intended to embrace all equivalents. Accordingly, under no circumstances whatsoever may these claims be interpreted as:

- having been altered in any way for any reason related to patentability;
- having been narrowed;
- a concession that the invention as patented does not reach as far as the original, unamended claim;
- a surrender of any subject matter as a condition of receiving a patent; and/or, estopping applicants from asserting infringement against every equivalent, whether now known or later developed, foreseen or unforeseen;

Applicants also emphasize that the decision to address the Examiner's suggestions via claim amendment with the understandings set forth above is not in any way intended to avoid the "gatekeeping" role of the PTO with regard to the examination and issuance of valid patents for patentable inventions.

## **I. ELECTION**

The Examiner acknowledges Applicants election with traverse of the species of Formula I wherein MH is araC; Z, W, and W' are hydrogen; and V is 4-pyridyl. The Examiner also notes that the full scope of claims 168-185 have been examined.

## **II. STATUTORY DOUBLE PATENTING**

The Examiner has rejected claims 168 and 180-185 under 35 U.S.C. § 101 as claiming the same invention as that of claims 95 and 168-173 of U.S. Patent No. 6,312,662.

The Applicants respectfully traverse this rejection.

Claims 95 and 168-173 of U.S. Patent No. 6,312,662 are compound claims, while the current claims are all pharmaceutical composition claims. It is also noted that the current claims require an additional limitation, "a pharmaceutically acceptable excipient." Therefore, claims 168 and 180-185 of the current application do not claim the same invention as claimed in claims 95 and 168-173 of U.S. Patent No. 6,312,662.

In view of the above, the Applicants respectfully request that the Examiner withdraw the statutory double patenting rejection.

## **III. OBVIOUSNESS TYPE DOUBLE PATENTING**

The Examiner has rejected claims 168-179 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 95-130 of U.S. Patent No. 6,312,662.

The Applicants are filing a properly executed terminal disclaimer along with this communication. As such, the Applicants respectfully request withdrawal of the double patenting rejection.

#### **IV. 35 USC § 112 REJECTIONS, SECOND PARAGRAPH**

##### ***A. Claims 169-173 and 177-179***

The Examiner has rejected claims 169-173 and 177-179 under 35 USC § 112, second paragraph as indefinite. The Examiner finds that the claims are ambiguous because “Applicant refers to the variable MH in Formula I, but there is no variable MH in Formula I. However, there is a variable M attached to the phosphorus in Formula A. Did the Applicant intend MH to be M?” (Office Action p. 4)

The Applicants respectfully traverse this rejection.

The Applicants did intend to use the term “MH.” The Applicants note that the specification at p. 21, lines 1-7 explains the relationship of M and MH:

The term “parent drug” refers to MH for phosph(oramid)ates where M is connected to  $-P(O)(OR)(OR)$  via oxygen, sulfur, or nitrogen, and  $M-PO_3^{2-}$  when M is connected to  $-P(O)(OR)(OR)$  via carbon. For example, AZT can be thought of as a parent drug in the form of MH. In the body AZT is first phosphorylated to AZT- $PO_3^{2-}$  and then further phosphorylated to form AZT-triphosphate, which is the biologically active form. The parent drug form MH only applies when M is attached via N, S or O. In the case of PMEA, the parent drug form is  $M-PO_3^{2-}$ .  
(specification p. 21, lines 1-7)

MH clearly refers to the parent drug. The parent drug MH is phosphorylated to become the biologically active drug. (see specification pp. 37-38).

Given the teaching in the specification, a person of ordinary skill in the art would not find the claims ambiguous and would have no difficulty in determining the scope of the claims. Therefore, the Applicants respectfully request that the Examiner withdraw the indefiniteness rejection.

***B. Claims 183, 184, and 185***

The Examiner has rejected claims 183, 184, and 185 under 35 USC § 112, second paragraph as indefinite. The Examiner argues that the claims are ambiguous “because the variable M in formula 1 has not been defined. In addition, M (see lines 20 and 21) has not been defined in MPO3H2 and MPO32-.” (Office Action pp. 4-5)

The Examiner also notes that “the claims were examined as if M is attached to the phosphorus of Formula I via a carbon, oxygen, or nitrogen atom.” (Office Action p. 5)

The Applicants respectfully traverse this rejection, as the Applicants believe that a person of ordinary skill in the art would be able to determine what M compounds are claimed by the present invention. However, in order to advance the prosecution of this application, the Applicants have amended claim 183-185 to further clarify the use of the term “M” in the claim.

In view of the above, the Applicants respectfully request that the Examiner withdraw the indefiniteness rejection.

***C. Claims 168 and 180-182***

The Examiner has rejected claims 168 and 180-182 under 35 USC § 112, second paragraph as indefinite. The Examiner contends that the claims are “confusing because of the proviso that ‘V, Z, W, and W’ are not all hydrogen’. In particular, the phrase is confusing because Z cannot be hydrogen (see definition of the variable Z).” (Office Action p. 5)

The Applicants respectfully traverse this rejection.

The claims in question define Z as “Z is selected from ... -R<sup>2</sup>...” and R<sup>2</sup> can be hydrogen. Therefore the Applicants believe that the proviso is not redundant or confusing.

In view of the above, the Applicants respectfully request that the Examiner withdraw the indefiniteness rejection.

## CONCLUSION

In view of the foregoing remarks, it is believed that the application is in condition for allowance, and such action is respectfully requested at the Examiner's earliest convenience.

Respectfully submitted,

Dated: 10/11/03

By: Diana L. Bush  
Diana L. Bush, Ph.D.  
Reg. No. 51,109

PAUL, HASTINGS, JANOFSKY & WALKER LLP  
3579 Valley Centre Drive  
San Diego, CA 92130  
Telephone: (858) 720-2500  
Facsimile: (858) 720-2555

Patent  
45198.00027.CON1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: **Erion *et al.***

Serial No.: **09/978,454**

Filed: **October 15, 2001**

Title: **NOVEL PRODRUGS FOR  
PHOSPHORUS-CONTAINING  
COMPOUNDS**

Group Art Unit: **1616**

Examiner: **Dameron Jones**

**TERMINAL DISCLAIMER UNDER 37 C.F.R. §1.321(B)**


Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Metabasis Therapeutics, Inc., a corporation duly organized under the laws of the State of Delaware, having a principal office located at 9390 Towne Centre Drive, San Diego, California 92121, and duly represented by the undersigned, represents that it is the assignee of the full title and interest in and to the above-identified Application Serial No. 09/978,454, filed October 15,

**CERTIFICATE OF TRANSMISSION**  
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

**JIN C. Youkel**  
Name of Person Transmitting Paper  
  
Signature of Person Transmitting Paper

October 1, 2003

Date of Transmission

2001, as evidenced by the deed of Assignment recorded on October 15, 2001 at Reel 012264, Frame 0962.

Metabasis Therapeutics, Inc., hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on Application Serial 09/978,454 which would extend beyond the expiration date of the full statutory term of prior U.S. Patent No. 6,312,662, the term being defined in 35 U.S.C. 154 to 156. Metabasis Therapeutics, Inc. hereby agrees that any patent granted on Application Serial No. 09/978,454 shall be enforceable only for and during such period that such patent and prior U.S. Patent No. 6,312,662, are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Metabasis Therapeutics, Inc. does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 of U.S. Patent No. 6,312,662, as presently shortened by any terminal disclaimer filed, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States

Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

The undersigned is an agent of record.

Patent  
45198.00027.CON1

The Commissioner is hereby authorized to charge Deposit Account No. 50-2613 for the fee due herein and any other fees that may become due or credit become payable during the pendency of this application.

Respectfully submitted,

Dated: October 1, 2003

By:

Cynthia H. O'Donohue  
Cynthia H. O'Donohue  
Reg. No. 44,980

**METABASIS THERAPEUTICS, INC.**  
9390 Towne Centre Drive, Bldg. 300  
San Diego, CA 92121